# US 11,078,289 B2 · Cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,289 B2
- Document ID: US11078289B2
- Status: Granted
- Kind: B2
- Application number: 16/357,249
- Filed: 2019-03-18
- Published: 2019-07-11
- Granted: 2021-08-03
- Earliest claimed: 2013-08-22
- Assignees: Vanda Pharmaceuticals Inc.
- Applicants: Vanda Pharmaceuticals Inc.
- Inventors: Mihael H. Polymeropoulos; Louis William Licamele; Christian Lavedan
- Web page: https://patentgrep.com/patent/US11078289B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

## Claims

### Claim 1

In a method of treating a patient diagnosed with cancer with trichostatin A (TSA), the improvement comprising:
selecting for treatment a patient determined to have increased aurora kinase A (AURKA) expression,
wherein the treating includes administering TSA to the selected patient in an amount sufficient to decrease an AURKA level in the selected patient, and
wherein TSA is the only AURKA inhibitor administered to the individual.

### Claim 2 (depends on 1)

The improvement of claim 1, wherein the amount of TSA is sufficient to inhibit histone deacetylase (HDAC) activity in the selected patient.

### Claim 3 (depends on 1)

The improvement of claim 1, wherein the amount of TSA is between about 0.1 mg/kg/day and about 10 mg/kg/day.

### Claim 4 (depends on 3)

The improvement of claim 3, wherein the amount of TSA is between about 0.5 mg/kg/day and about 5 mg/kg/day.

### Claim 5 (depends on 1)

The improvement of claim 1, wherein the cancer includes at least one cancer selected from a group consisting of: breast cancer, gastric cancer, colon cancer, rectal cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, lung cancer, hematological cancer, skin cancer, and malignancies.

### Claim 6 (depends on 1)

The improvement of claim 1, wherein the TSA is administered orally.

### Claim 7 (depends on 1)

The improvement of claim 1, wherein the TSA is administered intravenously.

### Claim 8 (depends on 1)

The improvement of claim 1, further comprising:
determining, from a tumor sample obtained from the selected patient's body, a level of aurora kinase A (AURKA) expression.

### Claim 9 (depends on 1)

The improvement of claim 1, wherein the cancer is breast cancer.